TNFRSF10D Human
Tumor necrosis factor receptor superfamily member 10D, CD264, DCR2, TRAIL-R4, TRAILR4, TRUNDD, Decoy receptor 2, TNF-related apoptosis-inducing ligand receptor 4, TRAIL receptor 4, TRAIL receptor with a truncated death domain.
Greater than 90.0% as determined by SDS-PAGE.
Description
TNFRSF10D produced in Sf9 Baculovirus cells is a single, glycosylated polypeptide chain containing 395 amino acids (56-211a.a.) and having a molecular mass of 73.8kDa. (Molecular size on SDS-PAGE will appear at approximately 40-57kDa).
TNFRSF10D is expressed with a 239 amino acid hIgG-His tag at C-Terminus and purified by proprietary chromatographic techniques.
Product Specs
TRAIL Receptor-4, also known as TNFRSF10D in humans, belongs to the TNF-receptor superfamily. TNFRSF10D is characterized by a truncated cytoplasmic death domain, an extracellular TRAIL-binding domain, and a transmembrane domain. This protein has the ability to inhibit TRAIL-induced apoptosis in cells expressing TRAIL R1 and/or TRAIL R2.
Produced using Sf9 Baculovirus cells, TNFRSF10D is a single, glycosylated polypeptide chain consisting of 395 amino acids (specifically, residues 56-211a.a.). It has a molecular mass of 73.8kDa. However, on SDS-PAGE, the apparent molecular size may fall within the range of 40-57kDa.
TNFRSF10D is expressed with a C-terminal 239 amino acid hIgG-His tag and purified through proprietary chromatographic techniques.
The TNFRSF10D protein solution is supplied at a concentration of 0.5mg/ml and is prepared in a buffer consisting of phosphate buffered saline (pH 7.4) with 10% glycerol.
SDS-PAGE analysis indicates a purity exceeding 90.0%.
Biological activity is assessed through a neutralizing assay employing Jurkat human T lymphocytes. The ED50, representing the effective concentration at which 50% neutralization is achieved, is less than or equal to 10 ng/ml in the presence of 2 ng/ml TRAIL.
Tumor necrosis factor receptor superfamily member 10D, CD264, DCR2, TRAIL-R4, TRAILR4, TRUNDD, Decoy receptor 2, TNF-related apoptosis-inducing ligand receptor 4, TRAIL receptor 4, TRAIL receptor with a truncated death domain.
ATIPRQDEVP QQTVAPQQQR RSLKEEECPA GSHRSEYTGA CNPCTEGVDY TIASNNLPSC LLCTVCKSGQ TNKSSCTTTR DTVCQCEKGS FQDKNSPEMC RTCRTGCPRG MVKVSNCTPR SDIKCKNESA ASSTGKTPAA EETVTTILGM LASPYHVEPK SCDKTHTCPP CPAPELLGGP
SVFLFPPKPK DTLMISRTPE VTCVVVDVSH EDPEVKFNWY VDGVEVHNAK TKPREEQYNS TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL PAPIEKTISK AKGQPREPQV YTLPPSRDEL TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPVL DSDGSFFLYS KLTVDKSRWQ
QGNVFSCSVM HEALHNHYTQ KSLSLSPGKH HHHHH.
Product Science Overview
TRAILR4 is a type 1 transmembrane protein that lacks a functional death domain, which is why it is referred to as a “decoy” receptor . Unlike other TRAIL receptors, such as death receptor 4 (DR4) and death receptor 5 (DR5), TRAILR4 does not induce apoptosis. Instead, it acts as a regulatory receptor that can inhibit TRAIL-induced apoptosis by competing with DR4 and DR5 for TRAIL binding .
TRAILR4 has garnered significant interest in cancer research due to its ability to modulate the apoptotic response in tumor cells. TRAIL, the ligand for TRAILR4, selectively induces apoptosis in cancer cells while sparing normal cells . This selective induction of cell death makes TRAIL and its receptors promising targets for cancer therapy .
Recombinant human TRAILR4 is produced using recombinant DNA technology, which involves inserting the gene encoding TRAILR4 into a suitable expression system, such as a bacterial or mammalian cell line. The recombinant protein is then purified and used for various research and therapeutic applications .
Recombinant TRAILR4 is used in research to study its role in apoptosis and cancer biology. It is also utilized in drug development to screen for potential therapeutic agents that can modulate TRAILR4 activity . Additionally, recombinant TRAILR4 can be used in diagnostic assays to measure the levels of TRAILR4 in biological samples .
